Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | Key takeaways from SABCS 2024: PATINA and other highlights

Claudine Isaacs • 16 Dec 2024
SABCS 2024
Breast Cancer Antibodies Palbociclib
AFT-38 PATINA

Claudine Isaacs, MD, Georgetown University, Washington, DC, provides an overview of highlights from the 2024 San Antonio Breast Cancer Symposium (SABCS), including omitting sentinel or axillary node dissection in patients receiving radiotherapy. The PATINA trial (NCT02947685) also demonstrated significant survival benefits with palbociclib in maintenance therapy, marking a potential shift in clinical practice. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Claudine Isaacs

Novel risk assessment models and resistance mechanisms in breast cancer genetics
2:04
Novel risk assessment models and resistance mechanisms in breast cancer genetics
Claudine Isaacs • 16 Dec 2024
Advances in breast cancer genetics: risk assessment & resistance mechanisms
3:31
Advances in breast cancer genetics: risk assessment & resistance mechanisms
Claudine Isaacs • 16 Dec 2024

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals